Among the editing sites we confirmed, chr12:69237004, chr12:69237010, chr12:69237013, and chr12:69237053 have been previously shown to be edited in breast cancer, 12 of 15 sites for MDM2, 8 of 9 sites for GINS1, 4 of 5 sites for F11R of editing sites were also confirmed in lymphoblastoid cells according to DARNED (Bahn et al. 2012; Ramaswami et al. 2012). This evidence concerns the gene F11R and breast carcinoma.